Objective: To investigate the efficacy of desonide cream combined with Heling emollient in the treatment of mild to moderate atopic dermatitis in infants. Methods: A total of 60 infants with atopic dermatitis treated in our hospital from June 2022 to June 2023 were randomly divided into the control group (n=30) and the observation group(n=30). The control group was treated with desonide cream alone, the observation group was treated with desonide cream combined with Heling emollient. Scoring atopic dermatitis (SCORAD) before and after treatment and the clinical efficacy were compared between the two groups of patients. Results: After 2 weeks of treatment, the SCORAD scores and clinical efficacy of two groups were both improved, and the SCORAD score and effective rate in the observation group were better than those in the control group (P＜0.05). The incidence rate of adverse reactions in the observation group and the control group was 3.33% and 16.66% respectively (P＞0.05). Conclusion: Desonide cream combined with Heling emollient can significantly reduce clinical symptoms and improve the therapeutic effect in infants with mild to moderate atopic dermatitis.
CAO Yuting
,
LI Jinmei
. Clinical efficacy of desonide cream combined with Heling emollient in treatment of mild to moderate atopic dermatitis in infants[J]. Journal of Baotou Medical College, 2024
, 40(10)
: 43
-45
.
DOI: 10.16833/j.cnki.jbmc.2024.10.009
[1] Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study[J]. Ann Allergy Asthma Immunol, 2021, 126(4): 417-428.e2.
[2] Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: across-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population[J]. J Invest Dermatol, 2019, 139(3): 583-590.
[3] Guo Y, Zhang H, Liu Q, et al. Phenotypic analysis of atopic dermatitis in children aged 1-12 months: elaboration of novel diagnostic criteria for infants in China and estimation of prevalence[J]. J Eur Acad Dermatol Venereol, 2019, 33(8): 1569-1576.
[4] 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020, 53(2): 81-88.
[5] 中华医学会皮肤性病学分会儿童皮肤病学组. 中国儿童特应性皮炎诊疗共识(2017版)[J]. 中华皮肤科杂志, 2017, 50(11): 784-789.
[6] Fleming P, Pease A, Ingram J, et al. Quality of investigations into unexpected deaths of infants and young children in England after implementation of national child death review procedures in 2008: a retrospective assessment[J]. Arch Dis Child, 2020, 105(3): 270-275.
[7] Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for eczema area and severity index (EASI), modified EASI, scoring atopic dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis[J]. Br J Dermatol, 2017, 177(5): 1316-1321.
[8] 林薇, 周琼艳, 黄静, 等. 特应性皮炎与精神神经因素相互作用的研究进展[J]. 中国医药导报, 2021, 18(5): 33-36.
[9] 管志伟, 刘欣欣, 李钦峰. 儿童特应性皮炎的皮肤微生态环境[J]. 中国实用儿科杂志, 2023, 38(9): 704-708.
[10] 李巍, 王上上, 刘玉峰. 老年特应性皮炎: 一个新的临床亚型[J]. 中华皮肤科杂志, 2020, 53(8): 654-657.
[11] Palmer CNA, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis[J]. Nat Genet, 2006, 38(4): 441-446.
[12] Leung DYM. Our evolving understanding of the functional role of filaggrin in atopic dermatitis[J]. J Allergy Clin Immunol, 2009, 124(3): 494-495.
[13] Henderson J, Northstone K, Lee SP, et al. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study[J]. J Allergy Clin Immunol, 2008, 121(4): 872-877.e9.
[14] 陈欣玥, 陈宗翰, 赵维佳. 地奈德乳膏联合复方多粘菌素B软膏治疗儿童中重度特应性皮炎[J]. 昆明医科大学学报, 2020, 41(12): 104-107.
[15] 申春平, 王华, 王榴慧, 等. 地奈德乳膏与丁酸氢化可的松乳膏治疗婴幼儿特应性皮炎的多中心、随机、平行对照临床研究[J]. 中华皮肤科杂志, 2019, 52(1): 11-15.
